Department of Psychosomatic Medicine, Kansai Medical University, Osaka, Japan.
Department of Psychosomatic Medicine, Kindai University, Osaka, Japan.
Ann Palliat Med. 2021 Oct;10(10):10244-10252. doi: 10.21037/apm-21-1503. Epub 2021 Aug 16.
Alexisomia is a clinical concept that describes difficulties in the awareness and expression of bodily feelings regarding physical diseases and symptoms. The study aim was to investigate whether incurable cancer patients with alexisomia had a higher incidence of latent trigger points, higher pain intensity, and higher pain-improvement goals.
A multicenter cross-sectional survey was conducted among patients with incurable cancer referred to a palliative care service at two university hospitals in Japan. Alexisomia was evaluated using the Shitsu-Taikan-Sho Scale (STSS). All patients were manually examined on their upper trapezius to identify latent trigger points. Patients who experienced pain reported their pain numerical rating scale (PNRS) and personalized pain goal (PPG) scores.
A total of 262 patients were selected as participants. Incurable cancer patients with alexisomia were observed in 30.2% of all participants [95% confidence interval (CI): 24.7-35.7]. The latent trigger points risk ratio in the alexisomic group versus the non-alexisomic group was 4.06 (95% CI: 2.24-7.37). Incurable cancer patients with alexisomia tended to have higher PNRS and PPG scores (P<0.001), but there was no significant difference in PPG achievement (P=0.641).
In examining incurable cancer patients with alexisomia, we must recognize that their latent trigger points risk ratio and PPGs are higher (lower symptom improvement goals) than cancer patients without alexisomia, and their rate of seeking help for pain may be low.
Alexisomia 是一种临床概念,描述了患者对身体疾病和症状的身体感觉的意识和表达方面的困难。本研究旨在调查是否患有无法治愈的癌症且存在 Alexisomia 的患者其潜伏触发点的发生率更高、疼痛强度更高以及疼痛改善目标更高。
在日本的两所大学医院的姑息治疗服务中,对患有无法治愈的癌症的患者进行了一项多中心横断面调查。使用 Shitsu-Taikan-Sho 量表(STSS)评估 Alexisomia。对所有患者的上斜方肌进行手动检查以识别潜伏触发点。经历疼痛的患者报告其疼痛数字评分量表(PNRS)和个性化疼痛目标(PPG)评分。
共选择了 262 名患者作为参与者。所有参与者中有 30.2%(95%置信区间:24.7-35.7)存在 Alexisomia。Alexisomic 组与非 Alexisomic 组的潜伏触发点风险比为 4.06(95%置信区间:2.24-7.37)。存在 Alexisomia 的无法治愈的癌症患者其 PNRS 和 PPG 评分较高(P<0.001),但 PPG 实现无显著差异(P=0.641)。
在检查患有 Alexisomia 的无法治愈的癌症患者时,我们必须认识到,与没有 Alexisomia 的癌症患者相比,他们的潜伏触发点风险比和 PPG 更高(较低的症状改善目标),且他们寻求疼痛帮助的可能性较低。